Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Objective The objective is to formulate clinical practice guidelines for the treatment of
diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more …

Background Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces
glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes …

Ketone body metabolism is a central node in physiological homeostasis. In this review, we
discuss how ketones serve discrete fine-tuning metabolic roles that optimize organ and …

Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly
reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal …

Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …